Abstract:Recent advances in the fields of thromboinflammation and immunothrombosis induced a paradigm shift integrating platelets as key components of the immune system, independent of their hemostatic functions. Platelets constitutively express a plethora of immune receptors such as toll-like receptors (TLRs), complement receptors, antibody receptors (FcR), and intracellular NOD-like receptors (NLRs) and, upon activation, can also upregulate and secrete an arsenal of immunomodulatory molecules, regulating both the innate and adaptive immune responses [<a href="#">1</a>,<a href="#">2</a>]. Although platelets were initially shown to promote a proinflammatory and prothrombotic state in sterile and infectious injuries, recent studies have shown protective roles for platelets during inflammation, in particular in the maintenance of vascular integrity, resolution of inflammation, and promotion of tissue repair [<a href="#">3</a>,<a href="#">4</a>]. More recently, platelet microvesicles have emerged as novel regulators of thrombo-inflammatory diseases, which, unto themselves, can regulate both innate and adaptive immunity [<a href="#">5</a>,<a href="#">6</a>]. Inflammatory/immune alteration of platelet function does not occur solely in periphery, but might also result from transcriptional and translational alteration in the genetic profile of megakaryocytes. The pro- or anti-inflammatory functions of platelets are highly dynamic with distinct receptors engaged in different vascular beds during the course of the inflammatory response. Likewise, the composition and structure of thrombi under inflammatory conditions is highly heterogeneous, dictated directly by the specific nature of the insult and the characteristics of the target vascular bed/organ. Moreover, recent studies have shown significant changes in the composition of the thrombi within the same organ during disease progression, increasing the complexity of successful treatment under thromboinflammatory conditions without global alteration of the hemostatic balance. Therefore, the success of novel anti-thrombotic drugs or the strategic repurposing of existing therapies will need to be tailored to each stimulus, organ, and disease state in an effort to limit both thrombosis and inflammation while simultaneously preserving vascular integrity and organ function.

Platelet‐inspired nanomedicine in hemostasis thrombosis and thromboinflammation

Advancement of Platelet-Inspired Nanomedicine

Platelet biology and functions: new concepts and clinical perspectives

Platelets in Hemostasis and Thrombosis: Novel Mechanisms of Fibrinogen-Independent Platelet Aggregation and Fibronectinmediated Protein Wave of Hemostasis

Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting

Engineering Unactivated Platelets for Targeted Drug Delivery

Nanotechnology and primary hemostasis: Differential effects of nanoparticles on platelet responses

Platelet-derived biomaterials for targeted drug delivery and tissue repair

A double-edged sword: The complex interplay between engineered nanoparticles and platelets

Recent advances in platelet engineering for anti-cancer therapies

Platelets: bridging thrombosis and inflammation

Translational Implications of Platelets as Vascular First Responders.

Cutting-edge advances in nano/biomedicine: A review on transforming thrombolytic therapy

Historical perspective and future directions in platelet research

Microfluidic systems toward blood hemostasis monitoring and thrombosis diagnosis: From design principles to micro/nano fabrication technologies

From bench to bedside: Platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery

Theranostic nanoparticles for the management of thrombosis

Platelets in Thrombosis and Atherosclerosis: A Double-Edged Sword

Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients?

Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond

Engineering Platelet-Mimicking Drug Delivery Vehicles